BioLargo Loss Narrows 47 Percent in Third Quarter
BioLargo reported third-quarter 2026 results on Tuesday, November 17, 2026, with revenue of $1.09 million, nearly flat against a year earlier, and a net loss of $3.82 million, down 47 percent. Its Aqueous Electrostatic Concentrator has been removing PFAS from municipal drinking water in Lake Stockholm, New Jersey since January, under federal and state monitoring.
Edited and fact-checked by Stephen Sprague
BioLargo's 2027 case rests on selling what it spent 2026 building. The December 1 annual meeting is the next dated checkpoint, and the Lake Stockholm unit's monitored results are the evidence to watch.
Since January, BioLargo's Aqueous Electrostatic Concentrator has been treating municipal drinking water in Lake Stockholm, New Jersey, while two regulators watch its output.
The Environmental Protection Agency and its New Jersey counterpart continue to monitor the unit's performance against state and federal standards. The company's third-quarter release, filed with its Form 10-Q on November 16, gives no removal percentage and no concentration figures for the Lake Stockholm water. What regulators measure there hasn't been published in the release.
Revenue was $1,090,000 in the third quarter, against $1,103,000 a year earlier, a decrease of 1 percent. Service revenue rose 72 percent and product revenue fell 32 percent. For the nine months, revenue was $3,452,000 against $7,148,000, a decrease of 52 percent.
The net loss was $3,824,000, against $7,244,000 a year earlier, a decrease of 47 percent that the company attributes mainly to a credit loss expense recorded last year. The nine-month net loss was $11,229,000, up 2 percent. Clyra Medical accounts for $6.4 million of that nine-month figure, about 57 percent, spent on personnel, manufacturing, product development and clinical work ahead of a 2027 product rollout.
Tonya Chandler, who leads BioLargo's equipment and technology subsidiary, said PFAS treatment requirements are spreading beyond drinking water to wastewater, landfill leachate, biosolids and industrial pre-treatment. She said lawsuit settlements in the billions are expected to fund treatment at public water systems, much of it for projects that haven't started.
Cash used in operations was $8,182,000 over the nine months, up 22 percent from a year earlier. The burn rate slowed inside the year. Cash use averaged about $736,000 a month in the third quarter, against about $996,000 a month in the first half, and Clyra raised $4,299,000, primarily through debt, while 77 percent of the capital raised came at the subsidiary level.
The rest of the portfolio is still pre-commercial. The barebird consumer odor line launched in October under a new subsidiary. The Cellinity grid-scale battery venture and the Tu Nipi oil sands water venture are both in discussions with potential strategic partners rather than in operation.
Chief Executive Dennis P. Calvert said the company expects 2027 to bring a shift in spending away from research and development and toward generating sales. That's a forecast, and the release labels its forward-looking statements as such. BioLargo holds its annual meeting on December 1, 2026 in Aliso Viejo, California, and it skipped the quarterly earnings call.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.